{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":28,"n_cols":5,"rows_kept":28,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[4,2,4,3],[9,2,9,3],[10,2,10,3],[11,2,11,3],[13,2,13,3],[15,2,15,3],[16,2,16,3],[20,2,20,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910678021603321"]
[null,null,"Titolo",null,"Pharmacometrics : the science of quantitative pharmacology / / edited by Ene I. Ette, Anoixis Corporation, Paul J. Williams, University of the Pacific and Anoixis Corporation"]
[null,null,"Pubbl/distr/stampa",null,"Hoboken, New Jersey : , : Wiley-Interscience, , [2007]"]
[{"$nulls":4},"©2007"]
[null,null,"ISBN",null,"1-118-67951-2"]
[{"$nulls":4},"1-280-82698-3"]
[{"$nulls":4},"9786610826988"]
[{"$nulls":4},"0-470-08797-8"]
[{"$nulls":4},"0-470-08796-X"]
[null,null,"Descrizione fisica",null,"1 online resource (1227 p.)"]
[null,null,"Classificazione",null,"44.38"]
[null,null,"Disciplina",null,"615.1"]
[{"$nulls":4},"615/.1"]
[null,null,"Soggetti",null,"Pharmacology"]
[{"$nulls":4},"Pharmacokinetics"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references and index."]
[null,null,"Nota di contenuto",null,"PHARMACOMETRICS; CONTENTS; CONTRIBUTORS; PREFACE; ACKNOWLEDGMENTS; 1. Pharmacometrics: Impacting Drug Development and Pharmacotherapy; PART I GENERAL PRINCIPLES; 2. General Principles of Programming: Computer and Statistical; 3. Validation of Software for Pharmacometric Analysis; 4. Linear, Generalized Linear, and Nonlinear Mixed Effects Models; 5. Bayesian Hierarchical Modeling with Markov Chain Monte Carlo Methods; 6. Estimating the Dynamics of Drug Regimen Compliance; 7. Graphical Displays for Modeling Population Data; 8. The Epistemology of Pharmacometrics; 9. Data Imputation"]
[{"$nulls":4},"PART II POPULATION PHARMACOKINETIC BASIS OF PHARMACOMETRICS10. Population Pharmacokinetic Estimation Methods; 11. Timing and Efficiency in Population Pharmacokinetic/Pharmacodynamic Data Analysis Projects; 12. Designing Population Pharmacokinetic Studies for Efficient Parameter Estimation; 13. Population Models for Drug Absorption and Enterohepatic Recycling; 14. Pharmacometric Knowledge Discovery from Clinical Trial Data Sets; 15. Resampling Techniques and Their "]
[{"$nulls":4},"Application to Pharmacometrics; 16. Population Modeling Approach in Bioequivalence Assessment"]
[{"$nulls":4},"PART III PHARMACOKINETICS / PHARMACODYNAMICS RELATIONSHIP: BIOMARKERS AND PHARMACOGENOMICS, PK/PD MODELS FOR CONTINUOUS DATA, AND PK/PD MODELS FOR OUTCOMES DATA17. Biomarkers in Drug Development and Pharmacometric Modeling; 18. Analysis of Gene Expression Data; 19. Pharmacogenomics and Pharmacokinetic/Pharmacodynamic Modeling; 20. Empirical Pharmacokinetic/Pharmacodynamic Models; 21. Developing Models of Disease Progression; 22. Mechanistic Pharmacokinetic/Pharmacodynamic Models I; 23. Mechanistic Pharmacokinetic/Pharmacodynamic Models II; 24. PK/PD Analysis of Binary (Logistic) Outcome Data"]
[{"$nulls":4},"25. Population Pharmacokinetic/Pharmacodynamic Modeling of Ordered Categorical Longitudinal Data26. Transition Models in Pharmacodynamics; 27. Mixed Effects Modeling Analysis of Count Data; 28. Mixture Modeling with NONMEM V; PART IV CLINICAL TRIAL DESIGNS; 29. Designs for First-Time-in-Human Studies in Nononcology Indications; 30. Design of Phase 1 Studies in Oncology; 31. Design and Analysis of Clinical Exposure: Response Trials; PART V PHARMACOMETRIC KNOWLEDGE CREATION; 32. Pharmacometric/Pharmacodynamic Knowledge Creation: Toward Characterizing an Unexplored Region of the Response Surface"]
[{"$nulls":4},"33. Clinical Trial Simulation: Theory34. Modeling and Simulation: Planning and Execution; 35. Clinical Trial Simulation: Efficacy Trials; PART VI PHARMACOMETRIC SERVICE AND COMMUNICATION; 36. Engineering a Pharmacometrics Enterprise; 37. Communicating Pharmacometric Analysis Outcome; PART VII SPECIFIC APPLICATION EXAMPLES; 38. Pharmacometrics Applications in Population Exposure-Response Data for New Drug Development and Evaluation; 39. Pharmacometrics in Pharmacotherapy and Drug Development: Pediatric Application"]
[{"$nulls":4},"40. Pharmacometric Methods for Assessing Drug-Induced QT and QTc Prolongations for Non-antiarrhythmic Drugs"]
[null,null,null,"Sommario/riassunto","Pharmacometrics is the science of interpreting and describing pharmacology in a quantitative fashion. The pharmaceutical industry is integrating pharmacometrics into its drug development program, but there is a lack of and need for experienced pharmacometricians since fewer and fewer academic programs exist to train them. Pharmacometrics: The Science of Quantitative Pharmacology lays out the science of pharmacometrics and its application to drug development, evaluation, and patient pharmacotherapy, providing a comprehensive set of tools for the training and development of pharmac"]